Blueprint Medicines (NASDAQ:BPMC) Trading Down 1.6% – Should You Sell?

Blueprint Medicines Co. (NASDAQ:BPMC)’s share price fell 1.6% during mid-day trading on Friday . The company traded as low as $88.20 and last traded at $88.37. 55,876 shares traded hands during trading, a decline of 94% from the average session volume of 1,000,307 shares. The stock had previously closed at $89.84.

Analyst Upgrades and Downgrades

BPMC has been the subject of several research reports. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. JPMorgan Chase & Co. boosted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Wedbush reiterated an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research note on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $125.21.

Blueprint Medicines Stock Down 0.3 %

The stock’s fifty day moving average is $99.46 and its two-hundred day moving average is $94.09. The company has a market capitalization of $5.72 billion, a PE ratio of -82.84 and a beta of 0.58. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now directly owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,608 shares of company stock worth $4,668,161. 4.21% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC bought a new position in shares of Blueprint Medicines during the fourth quarter valued at $103,356,000. Wellington Management Group LLP boosted its stake in Blueprint Medicines by 22.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after purchasing an additional 729,055 shares during the last quarter. Norges Bank bought a new stake in shares of Blueprint Medicines in the 4th quarter worth $62,028,000. State Street Corp raised its stake in shares of Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after purchasing an additional 385,818 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Blueprint Medicines during the fourth quarter valued at $31,417,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.